First Alzheimer's Vaccine Trial Tests Immune Response Against Amyloid Beta
A Phase 1 trial of AV-1959R, an Aβ-targeting vaccine, tests safety and antibody generation in healthy adults aged 40–60.
Summary
AV-1959R is an experimental vaccine designed to train the immune system to recognize and attack amyloid beta, the protein that accumulates in Alzheimer's disease. In this completed Phase 1 trial, 16 healthy adults aged 40–60 received three injections of either 100 µg or 300 µg of the adjuvanted vaccine or a placebo, spaced over 14 weeks. The primary goals were to confirm safety and tolerability, and to measure whether participants generated meaningful anti-amyloid beta antibody levels. A vaccine-based approach to Alzheimer's prevention could be transformative, potentially offering a scalable, cost-effective way to reduce amyloid burden before symptoms appear. Results from this small trial will inform dose selection and design for larger studies.
Detailed Summary
Alzheimer's disease remains one of the most devastating and costly conditions associated with aging, with no cure and limited disease-modifying treatments currently available. A preventive vaccine that trains the immune system to clear amyloid beta before plaques form could represent a paradigm shift in how we approach this illness.
This Phase 1 trial, sponsored by Nuravax, Inc., enrolled 16 healthy adults between the ages of 40 and 60 — a window considered important for early intervention before significant amyloid accumulation occurs. Participants received three intramuscular injections at weeks 0, 4, and 14 of either adjuvanted AV-1959R at 100 µg, 300 µg, or an adjuvanted placebo, followed by an 8-week monitoring period. The study's primary endpoints focused on safety and tolerability, with secondary endpoints measuring anti-Aβ antibody titers.
As a Phase 1 study, the principal objective was to establish that AV-1959R does not cause unacceptable side effects, particularly neuroinflammatory reactions — a concern that has historically plagued amyloid-targeting immunotherapy approaches. Generating measurable anti-amyloid antibodies in healthy, middle-aged adults would confirm the vaccine's immunogenicity and support progression to larger trials.
The implications are significant. Prior active immunization attempts for Alzheimer's, such as AN1792, were halted due to T-cell-mediated meningoencephalitis. Next-generation vaccines like AV-1959R are engineered to elicit antibody responses while minimizing inflammatory T-cell activity. If this trial demonstrates a clean safety profile with robust antibody generation, it could validate an entirely new prevention strategy for at-risk populations.
Caveats are substantial. The trial enrolled only 16 participants, making statistical conclusions premature. No efficacy data on cognitive outcomes or amyloid plaque reduction are expected at this stage. This summary is based on the abstract only, and full results have not yet been published.
Key Findings
- AV-1959R vaccine tested at two doses (100 µg and 300 µg) in healthy adults aged 40–60 to assess safety.
- Three-injection regimen over 14 weeks designed to generate measurable anti-amyloid beta antibodies.
- Phase 1 focus is safety and immunogenicity, not cognitive or clinical efficacy outcomes.
- Only 16 participants enrolled; trial is completed as of late 2025.
- Positive safety data could accelerate development of the first preventive Alzheimer's vaccine.
Methodology
Randomized, placebo-controlled Phase 1 trial with 16 healthy adults aged 40–60 receiving three IM injections of adjuvanted AV-1959R (100 µg or 300 µg) or placebo at weeks 0, 4, and 14, followed by 8-week follow-up. Primary endpoints: safety and tolerability. Secondary endpoints: anti-Aβ antibody response.
Study Limitations
This summary is based on the abstract only, and full trial data have not yet been published. The extremely small sample size (n=16) limits any statistical interpretation. No cognitive, imaging, or long-term safety outcomes are assessable at Phase 1.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.